Acceder

Farmas USA

135K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
3.415 / 16.989
#27313

Re: Farmas USA

Ana hoy vi al colega digestivo en un pasillo, la verdad que no tenia ni tus preguntas a mano ni el poster, así que le pregunte por Achillíon, me dijo que ni idea, despues me comento que de los que vio el que marca la diferencia es el sofosbuvir, por resultados en la tasa de curación, y porque además es free-interferon y es precisamente el interferon el que da los peores efectos adversos, de los que vio es el más avanzado y el que cree que tiene ventajas importantes frente a los ya aprobados.
Tambien me comento que hay más de 20 de está misma familia que se están estudiando, pero que no está al tanto de todos.

Como este miercoles es fiesta no podré verlo, pero para el siguiente ire preparado ok,
por cierto enteraté si el de achillíón es free-interferon.

Y por último no me dirás que GALE no está que se sale.

y tu ONVO mas: editado

Saludos

#27314

Re: Farmas USA

yehhh mamonassso, que yo voy largo en VVUS!!!!

Oye, has visto MJNA acercándose a ese retroceso fibo, que comentaste......
Yo, le he puesto orden de entrada.0.145

Edito: me acaban de entrar.
A juuuuuuuugar!!!!

#27315

Re: Farmas USA

me alegro campeón, pongo estas cosas para que la peña lo valore, sigo seco y con las mismas farmas, no seguí tu consejo de no darles el número de teléfono.

MJNA de todas formas andate con cuidado, no suelo poner gráficas en logarítmico y si la pones esta rota al tendencia alcista, pero tiene que rebotar en algun momento para coger camino a los 0,50.

soltastes intradia el anterior rebote del dia 24 con ganacias pillín.

#27317

Re: Farmas USA

ACHN

Ya no estoy. Si no recuerdo mal, hay combos con interferón y con ribavirina. Ya miraré quién tiene el sofosbuvir ese.

Sí, hoy me han salido varias lechugas bien hermosas. ONVO ya la he soltado y la espero otra vez en 3,42. Y barajo volver a entrar en CYTK.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#27318

Re: Mjna

si, lo vi (cuando se acababan de ejecutar) y hoy la está matando.Habrá que movilizar a los dealers y que se pongan en las calles con anuncios de neon a vender juana en plan mercadillo!

#27320

Re: Farmas USA

ARNA

Se convoca la junta general de accionistas: lunes, 10 de junio, 2013, at 9:00 a.m. (Pacific Time). El punto fuerte del orden del día es un plan de incentivos para los jefes a base de acciones. Me lo he leído en diagonal, pero no me gusta un pelo.

http://invest.arenapharm.com/secfiling.cfm?filingid=1193125-13-181345

To approve the Arena Pharmaceuticals, Inc., 2013 Long-Term Incentive Plan;

Subject to adjustment as provided in Section 12.2, a total of 30 million Shares shall be authorized for Awards granted under the Plan, as increased if applicable under this Section

La justificación: ¿una burda excusa?

We expect that the FDA approval, as well as the US commercialization of BELVIQ, the potential regulatory approval and commercialization of BELVIQ in additional territories around the world, and the advancement of our other programs, will bring uncertainty during this transition, and uncertainty brings risk that we will not be able to attract, retain and motivate personnel to execute on our long-term business plan. Our pay philosophy helps to mitigate this risk by using equity as an important component of our employees’ compensation. Along with incentivizing employees to increase stockholder value, vesting conditions, which generally occur over four years, have retentive value. As such, we believe that having stock available for grant is critical to our continuing development and success by helping to keep our employees focused on executing on our long-term business plan. We do not view the number of shares remaining available for grant under our current long-term incentive plan (the 2012 Long-Term Incentive Plan, or 2012 LTIP) as sufficient to allow us to execute on our long-term business plan, and an aggregate share reserve of 30 million shares under the 2013 LTIP was chosen to have shares available for grant for several years as we transition to a commercial-stage entity.

Otro párrafo interesante:

We Manage Our Award Use Carefully and Our Dilution is Reasonable. We seek to balance the need to attract and retain talented employees, as well as directors, consultants and advisors, in a highly competitive business with efforts to monitor our award “burn rate” each year. Our gross burn rate for the last three years is included in the below table, and we project that our gross burn rate for 2013 will be approximately 2.06%, which is the equivalent of approximately 4.5 million shares. Assuming that our expected gross burn rate for 2013 continues going forward, we estimate that the remaining shares under the 2012 LTIP would last for approximately two years after the end of 2013, as compared to approximately five years with respect to the shares under the 2013 LTIP. However, we do not as a matter of course make public forecasts as to our total shares outstanding and utilization of equity awards due to the unpredictability of the underlying assumptions and estimates. In particular, forecasts include assumptions regarding changes in the number and level of our employees, the type of equity awards we make, our potential growth and activities, changes in the granting of awards, the financial impact of grants and other factors, such as industry performance and general business, economic, regulatory, market and financial conditions, as well as factors specific to our business, all of which are difficult to predict and many of which are beyond our control.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

Brokers destacados